Clinic meets Biology

West German Lymphoma Symposium

24th and 25th May 2024 | Essen

Programme

Please enter your password to join the recordings.

Day 1 | Friday, 24th May 2024

from 09:30

Registration

10:45

Welcome
Scientific committee

11:00-1:00

Session 1
The germinal center reaction as
a catalyst for lymphoma development

Chair

Christian Reinhardt
University Hospital Essen (GER)

11:00

Role of Super-enhancer
Hypermutation in the

Pathogenesis of Diffuse
Large B cell Lymphoma

Riccardo Dalla-Favera,
Columbia University New York (USA)

11:25

Genetics-driven epigenetic disruption
of the
germinal center program
in B cell lymphomas

Laura Pasqualucci,
Columbia University New York (USA)

11:50

Aspects of Hodgkin lymphoma biology
Ralf KĂĽppers,
University Hospital Essen (GER)

12:15

Modelling Sporadic Oncogenic Events
in Lympho magenesis
Dinis Calado,
The Francis Crick Institute London (UK)

12:40

Short talk I –
Unveiling Follicular Lymphoma’s
Common Progenitor Cells

O. Atkins,
The Francis Crick Institute (UK)

12:50

Discussion

1:00-2:00

Break

2:00-4:00

Session 2
Epigenetic rewiring as a driver
and target of lymphomagenesis

Chair

Peter Borchmann
University Hospital Cologne (GER)

2:00

Mechanisms and therapeutic targeting
of the malignant immune system

Ari M. Melnick,
Weill Cornell Medicine New York (USA)

2:25

Development of small molecules
for epigenetic targets

Othman Al-Sawaf,
Universitätsklinikum Köln (GER)

2:50

Harnessing state switches
in aggressive B-cell lymphoma

Clemens Schmitt,
CharitĂ© – University Hospital Berlin (GER)

3:15

DNA-methylation based classification
of lymphomas: A tool to come?

Reiner Siebert,
Ulm University Hospital (GER)

3:40

Remote contribution
Toward the noninvasive characterization
of lymphomas & their microenvironments
Ash A. Alizadeh,
Stanford University / Stanford
Comprehensive Cancer Center (USA)

4:00-6:00

Poster presentation and
Get together

PO-01

Common Origins and Somatic Mutation
Patterns of Composite Lymphomas – Two
Models of Lymphomagenesis
V. Berg,
University Medicine Essen (GER)

PO-02

B Cell Differentiation in the Germinal
Centre Reaction
A.-K. Schnormeier,
University Duisburg-Essen (GER)

PO-03

DSMZCellDive: a web tool for browsing
and analyzing transcriptomic data of
hematological cell lines
S. Nagel,
Leibniz-Institute (GER)

PO-04

Distinct chemokine receptor expression
profiles in the development and early
progression of follicular lymphoma
A. Zupo,
Medical University of Graz (AUT)

PO-05 -WITHDRAWN

Functional vs. Genomic-based Precision
Medicine in Hematological Cancers:
Feasibility Analysis of the EXALT-2 Study
L. Kazianka,
Medical University of Vienna (AUT)

PO-06 – WITHDRAWN

Deep learning-based classification of
diffuse large B-cell lymphoma cell-of-
origin by gene expression profiles
K. Kundal,
Indian Institute of Technology Hyderabad (IND)

PO-07 AWARD WINNER 2024

LUBAC activity is required for ABC-DLBCL
pathogenesis
D. Bonasera,
University of Cologne (GER)

PO-08

A rationale for dual PIM and PI3K
inhibition in peripheral T-cell lymphoma
M. Lohrberg,
University Medical Center Göttingen (GER)

PO-09

Senolytic capacity of obinutuzumab in
t(14;18)-positive GCB DLBCL
M. Stegemann,
Kepler University Hospital (AUT)

PO-10

Identification of ferroptosis sensitizers for
DLBCL treatment
J. Labisch,
University Hospital MĂĽnster (GER)

PO-11

In vitro secretome analysis of primary
CLL cells and genetically modified B cells
L. Osswald,
Technial University of Munich (GER)

PO-12

Modulation of tumour microenvironment
by BIRC3-loss-of-function in CLL
S. Lyu,
University of Cologne (GER)

PO-13

Brusatol synergizes with venetoclax to
induce cell death in aggressive
lymphomas both in vitro and ex vivo.
M. M. Szmyra-Połomka,
Medical University of Graz (AUT)

PO-14

Detection of occurrent somatic
hypermutation and associated gene
expression profile in single follicular
lymphoma B cells
H. Veelken,
Leiden University Medical Center (NDL)

Unveiling Follicular Lymphoma’s
Common Progenitor Cells
O. Atkins,
The Francis Crick Institute (UK)

PO-15

Molecular analysis of B-cell dysfunction in
patients with chronic lymphocytic
leukemia (CLL)
M. Dampmann,
University Hospital Essen (GER)

PO-16

Understanding the role of cFLIP in the
pathogenesis of Diffuse Large B Cell
Lymphoma
K. T. Bariboloka,
University Hospital Cologne (GER)

PO-17

Machine-learning based body
composition analysis in patients
receiving CD19-directed CAR-T cell
therapy
F. Ullrich,
University Hospital Essen (GER)

PO-18 AWARD WINNER 2024

An In Vivo PiggyBac Insertional
Mutagenesis Screen Reveals Oncogenic
Lesions Cooperating With Myd88L265P
S. Höfmann,
University Hospital Essen (GER)

PO-19

IRF2BP2: A new player in diffuse large
B-cell lymphoma

A. Tabatabai,
University Hospital Essen (GER)
 

Day 2 | Saturday, 25th May 2024

8:00-10:00

Session 3
Genetic rewiring encodes actionable
vulnerabilities in lymphoma

Chair

Sascha Dietrich
University Hospital DĂĽsseldorf (GER)

8:00

Genetic bases of immune evasion in lymphoma
Margaret Shipp,
Dana Farber/Harvard Cancer Center
Boston (USA)

8:25

Curing aggressive lymphomas
with aggressive combinations
of targeted agents

Louis Staudt,
National Cancer Institute Bethesda (USA)

8:50

Actionable Alterations in LBCL
Björn Chapuy,
Charité University Medicine Berlin (GER)

9:15

Elucidation of Lymphoma Proteogenotypes
Thomas Oellerich,
University Hospital Frankfurt (GER)

9:40

Short talk II –
Autonomous B-cell receptor
signaling in
activated
B-cell DLBCL: A
lymphomagenic driver
with functional
equivalence
to an activating CARD11
variant
J. Eken,
Leiden University Medical Center (NLD)

9:50

Discussion

10:00-10:30

Break

10:30-12:00

Session 2
Epigenetic rewiring as a driver
and target of lymphomagenesis

Chair

Peter Borchmann
University Hospital Cologne (GER)

02:00

Ari M. Melnick
Weill Cornell Medicine New York (USA)

02:25

Stefan Knapp
Goethe-University Frankfurt (GER)

02:50

Clemens Schmitt
CharitĂ© – University Hospital Berlin (GER)

03:15

Rainer Siebert
Ulm University Hospital (GER)

09:40

Short talk II

09:50

Discussion

10:30-12:30

Session 4
The next frontier: harnessing the
immune system for lymphoma therapy

Chair

Bastian von Tresckow
University Hospital Essen (GER)

10:30

Chemotherapy free approaches
in first line LBCL – a dream or a reality?

Jason Westin,
University of Texas MD Anderson Cancer
Center Houston (USA)

10:55

Enhancing immunotherapies for germinal
center-derived B cell lymphomas by
EZH2 inhibition

Wendy BĂ©guelin,
Weill Cornell Medicine New York, (USA)

11:20

Multi-omic profiling of CAR T cell
treated aggressive B-cell
lymphoma reveals a CSF1R+
myeloid-monocytic cell
compartment mediating
CAR T cell resistance

Roland Ullrich,
University Hospital Cologne (GER)

11:45

Bispecific T Cell Engagers
in Follicular Lymphoma:
Promises and Path Ahead

Elisabeth Budde,
City of Hope National MedicalCenter Duarte (USA)

12:10

Multimodal and spatially resolved profiling
identifies distinct patterns of T cell infiltration
in nodal B cell lymphoma entities

Sascha Dietrich,
University Hospital DĂĽsseldorf (GER)

12:35

Discussion

12:45-1:45

Break

1:45-3:30

Session 5
Mechanisms of resistance and
definition of high-risk DLBCL

Chair

Ralf KĂĽppers
University Hospital Essen (GER)

1:45

Short talk III –
Targeting N-linked
Glycosylation for the
Therapy of Aggressive
Lymphomas

S. Scheich,
Goethe University Frankfurt,
University Hospital Frankfurt,
Frankfurt, Germany

1:55

Mechanisms of resistance and
definition of high-risk DLBCL
Andrew Davies,
Southampton General Hospital (UK)

2:20

Overcoming therapy resistance
through single-cell functional precision
medicine approaches
Philipp Staber,
Medical University of Vienna (AUT)

2:45

Autochthonous mouse models of DLBCL
enable in vivo genetic screening and
serve as a platorm for preclinical validation
of actionable vulnerabilities
Christian Reinhardt,
University Hospital Essen (GER)

3:10

Discussion

3:30

Closing remarks
Farewell and Goodbye

Status 05/2024, subject to change.

WordPress Cookie-Hinweis von Real Cookie Banner